NCT06829199 2026-02-19
MK-5890-003
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
Clinical Trials
4 trialsNCT03554109 2025-02-21
TNBC
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT02637375 2016-05-30
A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer
University of Chicago
Phase NA Withdrawn
NCT01333423 2012-06-26
Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center
Phase 1 Withdrawn